Tscan Therapeutics Inc

+0.04 (+2.22%)
7:47:32 PM EDT: $1.85 +0.01 (+0.54%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)34.84M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$4.1 Million
Adjusted EPS-$0.72
See more estimates
10-Day MA$1.83
50-Day MA$1.90
200-Day MA$2.72
See more pivots

Tscan Therapeutics Inc Stock, NASDAQ:TCRX

830 Winter Street, Waltham, Massachusetts 02451
United States of America
Phone: +1.857.399.9500
Number of Employees: 105


TScan Therapeutics, Inc. discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors and other serious diseases. Its platform identifies previously uncharacterized, clinically-derived shared T cell antigens and all off-target TCR interactions, to enable the development of efficacious TCR-Ts. The company was founded by Christoph H. Westphal, Stephen Elledge, Lea Hachigian, and Tomasz Kula in 2018 and is headquartered in Boston, MA.